Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 3;13:6497–6509. doi: 10.2147/OTT.S256818

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Wei et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Validation of the 6-EMT gene signature in the MDACC-based cohort of the GEO dataset (GSE25066). (A) A time-dependent ROC curve for 18 months among the TNBC patients with residual disease after NACT. The cut-off value was generated with the highest specificity and sensitivity (Youden Index). (B) The distribution of the prognostic values of the TNBC patients with residual disease (top panel) and the corresponding distant relapse-free survival for each patient (bottom panel). Patients were divided into high-risk (right part) and low-risk (left part) groups by a line in the diagram, according to the cut-off value (0.126). (C) Kaplan–Meier analysis of the probability of metastasis-free survival of the patients with residual disease post-NACT in the MADACC cohort.

Abbreviations: EMT, epithelial–mesenchymal transition; ROC, receiver operating characteristic curve; AUC, area under curve; RD, residual disease; HR, hazard ratio; TNBC, triple-negative breast cancer; NACT, neoadjuvant chemotherapy.